Literature DB >> 30944260

Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s.

Joshua Kellner1, Caroline Wallace1, Bei Liu1,2, Zihai Li1,2,3.   

Abstract

Multiple myeloma (MM) is an incurable plasma cell malignancy with frequent treatment failures and relapses, suggesting the existence of pathogenic myeloma stem/progenitor populations. However, the identity of MM stem cells remains elusive. We used a murine model of MM with transgenic overexpression of the unfolded protein response sensor X-box binding protein 1 (XBP1s) in the B cell compartment to define MM stem cells. We herein report that a post-germinal center, pre-plasma cell population significantly expands as MM develops. This population has the following characteristics: (a) cell surface phenotype of B220+CD19+IgM-IgD-CD138-CD80+sIgG-AA4.1+FSChi; (b) high expression levels of Pax5 and Bcl6 with intermediate levels of Blimp1 and XBP1s; (c) increased expression of aldehyde dehydrogenase, Notch1, and c-Kit; and (d) ability to efficiently reconstitute antibody-producing capacity in B cell-deficient mice in vivo. We thus have defined a plasma cell progenitor population that resembles myeloma stem cells in mice. These results provide potentially novel insights into MM stem cell biology and may contribute to the development of novel stem cell-targeted therapies for the eradication of MM.

Entities:  

Keywords:  B cells; Hematology; Immunoglobulins; Immunology; Mouse stem cells

Mesh:

Substances:

Year:  2019        PMID: 30944260      PMCID: PMC6483640          DOI: 10.1172/jci.insight.124698

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  82 in total

1.  Plasma cell differentiation requires the transcription factor XBP-1.

Authors:  A M Reimold; N N Iwakoshi; J Manis; P Vallabhajosyula; E Szomolanyi-Tsuda; E M Gravallese; D Friend; M J Grusby; F Alt; L H Glimcher
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

2.  Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells.

Authors:  Miki Nakamura; Tomomi Gotoh; Yutaka Okuno; Hiro Tatetsu; Takashi Sonoki; Shima Uneda; Masataka Mori; Hiroaki Mitsuya; Hiroyuki Hata
Journal:  Leuk Lymphoma       Date:  2006-03

3.  CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche.

Authors:  Stéphane Chevrier; Céline Genton; Axel Kallies; Alexander Karnowski; Luc A Otten; Bernard Malissen; Marie Malissen; Marina Botto; Lynn M Corcoran; Stephen L Nutt; Hans Acha-Orbea
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

4.  Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells.

Authors:  Katia Basso; Masumichi Saito; Pavel Sumazin; Adam A Margolin; Kai Wang; Wei-Keat Lim; Yukiko Kitagawa; Christof Schneider; Mariano J Alvarez; Andrea Califano; Riccardo Dalla-Favera
Journal:  Blood       Date:  2009-12-03       Impact factor: 22.113

5.  XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.

Authors:  Tina Bagratuni; Ping Wu; David Gonzalez de Castro; Emma L Davenport; Nicholas J Dickens; Brian A Walker; Kevin Boyd; David C Johnson; Walter Gregory; Gareth J Morgan; Faith E Davies
Journal:  Blood       Date:  2010-04-26       Impact factor: 22.113

Review 6.  VLA-4-dependent myeloma cell adhesion.

Authors:  F Sanz-Rodríguez; J Teixidó
Journal:  Leuk Lymphoma       Date:  2001-04

Review 7.  Tumor microenvironment and drug resistance in hematologic malignancies.

Authors:  Zhi-Wei Li; William S Dalton
Journal:  Blood Rev       Date:  2006-08-22       Impact factor: 8.250

8.  Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice.

Authors:  Giorgio Cattoretti; Laura Pasqualucci; Gianna Ballon; Wayne Tam; Subhadra V Nandula; Qiong Shen; Tongwei Mo; Vundavalli V Murty; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

9.  Essential roles of IL-12 and dendritic cells but not IL-23 and macrophages in lupus-like diseases initiated by cell surface HSP gp96.

Authors:  Jie Dai; Bei Liu; Daniel J Cua; Zihai Li
Journal:  Eur J Immunol       Date:  2007-03       Impact factor: 5.532

10.  In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain.

Authors:  P L Bergsagel; A M Smith; A Szczepek; M J Mant; A R Belch; L M Pilarski
Journal:  Blood       Date:  1995-01-15       Impact factor: 22.113

View more
  5 in total

Review 1.  Molecular basis of clonal evolution in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2020-02-06       Impact factor: 2.490

Review 2.  Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?

Authors:  David Kegyes; Catalin Constantinescu; Louise Vrancken; Leo Rasche; Celine Gregoire; Bogdan Tigu; Diana Gulei; Delia Dima; Alina Tanase; Hermann Einsele; Stefan Ciurea; Ciprian Tomuleasa; Jo Caers
Journal:  J Hematol Oncol       Date:  2022-06-07       Impact factor: 23.168

3.  MicroRNA-664 suppresses the growth of cervical cancer cells via targeting c-Kit.

Authors:  Mingfen Lv; Rongying Ou; Qianwen Zhang; Fan Lin; Xiangyun Li; Keyu Wang; Yunsheng Xu
Journal:  Drug Des Devel Ther       Date:  2019-07-17       Impact factor: 4.162

4.  Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.

Authors:  Lingzhi Yan; Su Qu; Jingjing Shang; Xiaolan Shi; Liqing Kang; Nan Xu; Mingqing Zhu; Jin Zhou; Song Jin; Weiqin Yao; Ying Yao; Guanghua Chen; Huirong Chang; Xiaming Zhu; Lei Yu; Depei Wu; Chengcheng Fu
Journal:  Cancer Med       Date:  2020-12-23       Impact factor: 4.452

Review 5.  Notch Signaling in B Cell Immune Responses.

Authors:  Matthew Garis; Lee Ann Garrett-Sinha
Journal:  Front Immunol       Date:  2021-02-05       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.